ArticleJournal of Taibah University Medical Sciences2026
Role of Nkx2.2 immunohistochemistry in distinguishing Ewing sarcoma from neuroendocrine neoplasms at different sites.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Ewing sarcoma is a high grade round cell sarcoma that exhibits considerable histomorphological overlap with other round cell tumors, especially neuroendocrine neoplasms. In the present study, we compared the immunohistochemical expression of Nkx2.2 in cases of Ewing's sarcoma, neuroendocrine neoplasms at different sites, and a small subset of other mesenchymal and nonmesenchymal tumors in order to assess its utility in their distinction. Materials and methods: This descriptive retrospective study lasted for 14 months and investigated 60 cases, with 17 cases of Ewing sarcoma, 34 cases of neuroendocrine neoplasms and nine cases of other tumors. Hematoxylin and eosin and Nkx2.2 immunohistochemistry-stained slides of previously diagnosed cases were retrieved and reviewed. Results: Nkx2.2 exhibited sensitivity of 88.2% and specificity of 53.4% in the diagnosis of Ewing's sarcoma. Nkx2.2 expression was also present in neuroendocrine neoplasms (especially those of gastrointestinal and pancreatic origins) with 52.9% sensitivity and 34.6% specificity. Other neuroendocrine neoplasms that were positive for Nkx2.2 included those of prostate, female genital tract, and larynx origins. Among other tumors, pleomorphic sarcoma and melanoma exhibited Nkx2.2 positivity. Most cases (83.3%, 5/6) of lung neuroendocrine neoplasms were negative for Nkx2.2. Conclusion: Nkx2.2 exhibited high sensitivity in diagnosing Ewing's sarcoma and certain neuroendocrine neoplasms (especially those of gastrointestinal and pancreatic origins), but its lower specificity and varied expression across other tumor types highlight the need for a cautious and context-specific approach when used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.